|
|
||||||||
J Thorac Cardiovasc Surg 1996;112:557
© 1996 Mosby, Inc.
LETTERS TO THE EDITOR |
Department of Cardiac Surgery
University Hospital of Antwerp
Edegem, Belgium
To the Editor:
We read with interest the recently published paper by Gorman and associates
1 on surface-bound heparin in extracorporeal circuits. The study was well conceived and conducted. Several questions remain, however. The first question concerns the appropriateness of including several of the patients in the study. Four of the 20 patients, two in each group, underwent pulmonary arterial thrombectomy. Circulatory arrest of relatively long duration was applied in all, and at low body temperatures, varying from 12° to 14.9° C. Extreme hypothermia can result in severe disturbances in coagulation.
2 The prolonged circulatory arrest in these patients suggests the presence of great quantities of thrombotic material. If these thrombi had been recently formedand this was not stated in the paperthey may have resulted in significant consumption of coagulation factors. In our opinion these three patients should not have been included in the study.
Second, the authors state that a Cell Saver System (Haemonetics, Braintree, Mass.), was used in all patients, implying extensive contact between blood and uncoated synthetic material. Washing blood with normal saline solution results in removal of plasma, which would also greatly affect coagulation. In addition, no mention was made of how much blood per patient was so treated.
Third, experimental and clinical studies have shown that heparin-coated circuits yield some attenuation of inevitable damage to blood components, but that the difference with uncoated circuits is slight. We were therefore surprised that the study's conclusions correspond entirely with those of our animal experimental research,
3,4 despite the possible shortcomings of the methods. Our study used a venovenous coated or uncoated circuit with low flow in unheparinized dogs. We, too, found some protection of circulating blood by coated circuits, and we also found no reduction in blood coagulability. We therefore agree with the authors' conclusion that reducing the dose of heparin when a heparin-coated system is used, as is advocated by some,
5 is unwise and even dangerous.
References
This article has been cited by other articles:
![]() |
A. M. Skrzypchak, N. G. Lafayette, R. H. Bartlett, Zhengrong Zhou, M. C. Frost, M. E. Meyerhoff, M. M. Reynolds, and G. M. Annich Effect of varying nitric oxide release to prevent platelet consumption and preserve platelet function in an in vivo model of extracorporeal circulation Perfusion, May 1, 2007; 22(3): 193 - 200. [Abstract] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |